Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.

Objective: The primary endpoint of the study was to determine the proportion of patients with HIV RNA < 50 copies/mL at 48 weeks. Design: Phase IV, multicentric, open-label, single-arm clinical trial of participants recruited in 2018−2019 to evaluate the efficacy and safety of tenofovir alafenamide/emtricitabine/elvitegravir-cobicistat (TAF/FTC/EVG-c) as first-line treatment in HIV-1 infected naïve participants with advanced disease. Methods: Adverse events were graded according to the Division of AIDS scale version 2.0. Quantitative variables were recorded as median and interquartile range, and qualitative variables as absolute number and percentage. T-Student or Wilcoxon tests were used to analyze intragroup differences of the continuous variables. Results: Fifty participants were recruited with a baseline median CD4 lymphocyte count of 116 cells/µL and a viral load of 218,938 copies/mL. The proportion of patients with viral load <50 copies/mL at week 48 was 94% in the per-protocol analysis, with a median time of 1.9 months to achieve it. Three adverse events attributed to the study drug caused trial discontinuation. Conclusions: the use of TAF/FTC/EVG-c in patients with advanced HIV disease in our study demonstrated efficacy comparable to data from pivotal clinical trials with a good safety profile.

Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial.

OBJECTIVES: To evaluate whether simplification of antiretroviral treatment to dual therapy (DT) negatively impacts immune recovery (IR), immune activation and inflammation (IA/I), and HIV reservoir. METHODS: An open-label, single-centre, randomized controlled trial conducted in adult virologically suppressed HIV-infected patients on triple therapy (TT) with elvitegravir-cobicistat, emtricitabine and tenofovir alafenamide or dolutegravir (DTG), abacavir, and lamivudine (3TC). Participants were randomized to continue TT or switch to DTG, or darunavir/cobicistat (DRVc) plus 3TC. IR was assessed by CD4+/CD8+ ratio at 48 and 96 weeks. Changes in immune activation, proliferation, exhaustion, senescence, and apoptosis in CD4+ and CD8+ T cells, plasma sCD14, hsCRP, D-dimers, ß2-microglobulin, IL-6, TNF-α and IP-10 levels, cell-associated HIV-DNA (CA-DNA), and unspliced HIV-RNA (usRNA) were also analysed. RESULTS: One hundred and fifty-one participants were enrolled. Fourteen patients did not complete the follow up. In the ITT and PP analysis, the IR was similar between the treatment arms. In the ITT analysis, the median increase in CD4+/CD8+ ratio was 0.10, 0.04, and 0.07 at week 48, and 0.09, 0.05, and 0.08 at week 96 for TT, DTG/3TC, and DRVc/3TC, respectively. After adjusting for confounding factors, the slopes of changes in CD4+/CD8+ ratio over time were independent of treatment (F = 1.699; p = 0.436) and related only to baseline values (F = 756.871; p = 0.000). There were no differences in IA/I, CA-DNA, or usRNA between treatment arms. DISCUSSION: Both IR and IA/I, CA-DNA, and usRNA were similar in the three treatment groups, regardless of maintaining TT or simplifying to DTG/3TC or DRVc/3TC in virologically suppressed HIV-infected patients.

Cultural Adaptation and Psychometric Properties of the Shirom-Melamed Vigor Measure (SMVM) With Workers in Spain.

Shirom's proposal about engagement focuses on vigor. Under this approach, vigor is considered an affect that mediates the relationship between resources, behaviors, and attitudes related to psychological functioning and health. It is important for occupational health professionals to have adequate measures of this construct. The Shirom-Melamed vigor measure (SMVM) was developed to capture this sense of energy comprising three components (physical strength, emotional energy, and cognitive liveliness). In the absence of a Spanish version of the SMVM, our aim is to perform a cultural adaptation and to further analyze its psychometric properties. In Study 1, we culturally adapt the SMVM in Spanish samples. It incorporates a careful development of a three-step procedure according to the International Test Commission and qualitative analyses to ensure a consensus version. Twenty-six individuals were involved. In Study 2, the responses of 203 workers from different organizations show the validity and reliability of the instrument. Confirmatory factor analyses yield a model with three interrelated dimensions showing good fit indices. Furthermore, concurrent validity is demonstrated. Finally, we discuss the usefulness of the SMVM for occupational health professionals.

Transforming a Compact Disk into a Simple and Cheap Photocatalytic Nanoreactor.

A commercial compact disk has been converted into an effective photocatalytic nanoreactor by depositing a catalyst layer inside the nanochannels by means of an electrophoretic method. The resultant device has been tested for water splitting, obtaining a high yield of hydrogen at an unbeatable low cost.

Simultaneous in situ generation of hydrogen peroxide and Fenton reaction over Pd-Fe catalysts.

High mineralization degree of organic compounds can be achieved by a novel environmentally-friendly full heterogeneous Pd-Fe catalytic system, which involves in situ generation of hydrogen peroxide from formic acid and oxygen, and oxidation of organic compounds by Fenton process in a one-pot reaction.